

Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis

Matthias Barton

Received: 14 March 2010 / Accepted: 17 June 2010 / Published online: 16 July 2010
© Springer-Verlag 2010

Abstract Endothelial cells are both the source and target of factors contributing to atherosclerosis. After the discovery of the endothelium-derived relaxing factor (EDRF) by Robert F. Furchgott in 1980 it soon became clear that endothelial cells also release vasoactive factors distinct from nitric oxide (NO) namely, endothelium-derived contracting factors (EDCF) as well as hyperpolarizing factors (EDHF). Vasoactive factors derived from endothelial cells include NO/EDRF, reactive oxygen species, endothelins and angiotensins which have either EDRF or EDCF functions, cyclooxygenase-derived EDCFs and EDRFs, and EDHFs. Endothelial factors are formed by enzymes such as NO synthase, cyclooxygenase, converting enzymes, NADPH oxidases, and epoxigenases, among others, and participate in the regulation of vascular homeostasis under physiological conditions; however, their abnormal regulation due to endothelial cell dysfunction contributes to disease processes such as atherosclerosis, arterial hypertension, and renal disease. Because of recent changes in world demographics and the declining health status of the world's population, both aging and obesity as independent risk factors for atherosclerosis-related diseases such as coronary artery disease and stroke, will continue to increase in the years to come. Obesity and associated conditions such as arterial hypertension and diabetes are now also some of the primary health concerns among children and adolescents. The similarities of pathomechanisms activated in obesity and aging suggest that obesity—at least in the vasculature—can

be considered to have effects consistent with accelerated, “premature” aging. Pathomechanisms as well as the clinical issues of obesity- and aging-associated vascular changes important for atherosclerosis development and prevention are discussed.

Keywords Aging · Vascular · Obesity · Nitric oxide · Endothelin · Endothelial cell · Vascular smooth muscle cell

The discovery of endothelium-dependent control of vascular function

Endothelial cell research gained particular interest among physiologists and physicians only in the last 20 years of the twentieth century [46]. Endothelial cells form the inner lining of arterial and venous blood vessels and amount to approximately 1.5 kg, covering an area of approximately four tennis courts [78]. Under normal conditions, endothelial cells constantly produce a number of vasoactive and trophic substances that control inflammation, vascular smooth muscle cell growth, vasomotion, platelet function, and plasmatic coagulation [8, 129]. In the early 1970s, Ross and Glomset reported that endothelial cells exert a protective effect preventing smooth muscle cells to proliferate, which generated the “response-to-injury” theory of atherosclerosis [110]. Since 1980, following the seminal observation of Robert F. Furchgott that endothelial cells release vasoactive factors that modulate vascular tone [47, 98], many advances have been made with regard to understanding how endothelial cell-derived factors both contribute to and interfere with the development of a number of cardiovascular pathologies [16, 129]. These factors, which are formed not only by endothelial cells but also by other cells such as vascular smooth muscle cells or

This article is published as part of the special issue on “The Endothelial Saga: The Heritage of Robert F. Furchgott”

M. Barton (✉)
Molecular Internal Medicine, University of Zurich,
LTK Y44 G22, Winterthurerstrasse 190,
CH-8057 Zürich, Switzerland
e-mail: barton@access.uzh.ch

mesangial cells, are now known to contribute to the abnormal regulation of vascular tone and cell growth [7]. A selection of the most important factors identified so far that have been extensively studied in numerous physiological and pathophysiological conditions [134] have been summarized in Table 1. Research of the past three decades has provided evidence that inhibition of detrimental pathways such as blocking reactive oxygen species or receptors for endothelin or angiotensin, or increasing NO bioactivity can attenuate inflammation and subsequent disease progression and will have beneficial effects on disease outcome and survival [6, 16, 129].

Endothelium-derived vasodilators

The cyclooxygenase product, *prostacyclin* (prostaglandin I_2), was discovered in the early 1970s by Vane and associates [132]. Prostacyclin is formed by endothelial and other cells and has vasodilator and growth inhibitory activity [40, 90, 134]. The release of the *endothelium-derived relaxing factor (EDRF)* in response to acetylcholine was discovered by Furchgott in 1980, after both Vanhoutte [133] and Toda [126] in 1974 independently reported vascular relaxation in response to the muscarinic agonist.

Furchgott provided proof that this vasorelaxation requires endothelial cells to release an unstable dilator factor [47]. The identity of *EDRF* as *nitric oxide (NO)* was independently demonstrated by Furchgott and by Ignarro in the mid-1980s [46, 63]. Endothelium-derived NO, formed by endothelial nitric oxide synthase (isoform 3, NOS3) by genomic and non-genomic mechanisms, as well as by a variety of post-translational modifications including phosphorylation [44], is not only a vasodilator but also inhibits cell growth and inflammation [49, 109]. Endothelium-dependent NO-independent dilatation is largely mediated by hyperpolarization, and a number of *endothelium-derived hyperpolarizing factors (EDHFs)* have been identified. They include epoxyeicosatrienoic acids (EETs), which are cytochrome P-450 metabolites, H_2O_2 , endothelial gap junction communication, and potassium [reviewed in 27, 28]. Different EDHFs may also interfere with each other [74] (Table 1). *Endothelins* are endothelial cell-derived vasoactive peptides. Both ET-1 and ET-3 (see below) exert vasodilator activity through activation of endothelial cell ET_B receptors [7] and subsequent formation of NO [60]. *Angiotensins* are also formed by endothelial cells. Angiotensin II—through the endothelial AT_2 receptor [78]—and its break-down products, Ang 1-7, through its receptor MAS [112] and angiotensin IV (Ang 3-8)

Table 1 A selection of known endothelial cell-derived substances with either vasodilator or vasoconstrictor activity

Molecule	Source/enzyme	Target/receptor
Endothelium-derived vasodilators		
NO/EDRF	NOS3	VSMC, soluble guanylate cyclase
PGI_2 /Prostacyclin	Cyclooxygenase-1 and 2	Prostacyclin receptor (IP)
EETs/EDHF	EDHF synthase/cytochrome P_{450} epoxygenase	VSMC, SK(Ca) and IK(Ca) channels
H_2O_2 /EDHF	Catalase	VSMC, SK(Ca) and IK(Ca) channels
K^+ /EDHF		VSMC, SK(Ca) and IK(Ca) channels
Gap junctions/EDHF		VSMC, TRPV4 and SK(Ca) channels
Endothelin-1	ECE-1, ECE-2 chymase, VSMC chymase	NOS3, EC endothelin ET_B receptor
Endothelin-3	ECE-1, ECE-3	NOS3, EC endothelin ET_B receptor
Angiotensin II	ACE	NOS3, EC angiotensin AT_2 receptor
Angiotensin 1-7	ACE2	NOS3, EC MAS receptor
Endothelium-derived vasoconstrictors		
Prostanoids/EDCF	Arachidonic acid; cyclooxygenase-1	VSMC; thromboxane receptor (TP)
Thromboxane A_2	Thromboxane synthase	VSMC; thromboxane receptor (TP)
O_2^- /superoxide	NADPH oxidase/NOX4	NO inactivation and ONOO $^-$ formation
O_2^- /superoxide	EDHF synthase/cytochrome P_{450} epoxygenase	NO inactivation and ONOO $^-$ formation
Endothelin-1	ECE-1, ECE-2	VSMC; endothelin ET_A receptor
Angiotensin II	ACE	VSMC; angiotensin AT_1 receptor

ACE angiotensin converting enzyme, ACE2 angiotensin converting enzyme-2, Cyt cytochrome, EC endothelial cell, ECE endothelin converting enzyme, EDHF endothelium-derived hyperpolarizing factor, EDRF endothelium-derived relaxing factor, EET epoxyeicosatrienoic acids, IK(Ca) intermediate conductance Ca(2+) activated K(+) channel, VSMC vascular smooth muscle cell, NOS NO synthase, ONOO $^-$ peroxynitrite, O_2^- superoxide anion, TP thromboxane receptor, TRP transient receptor potential, SK(Ca) small conductance Ca(2+) activated K(+) channel

through the AT₄ receptor [59, 102, 137], cause endothelium-dependent dilation, involving activation of eNOS/cGMP.

Endothelium-derived vasoconstrictors

Arachidonic acid-derived *vasoconstrictor prostanoids* were the first endothelium-derived contracting factors (*EDCFs*) and identified by DeMey and Vanhoutte, who demonstrated contractile effects mediated by cyclooxygenase products shortly after the report of endothelium-dependent dilation [38]. *Superoxide anion*, a short-lived by-product of oxidative metabolism, was also found to have vasoconstrictor activity again by Vanhoutte's group [111] and also by Moncada and associates [56]. This effect is largely due to the EDRF/NO-inactivating properties of the superoxide anion [111]. The source of reactive oxygen species has been studied since the early 1990s and Griending and coworkers have identified a vascular NADPH oxidase (NOX) as one of the major sources of vascular reactive oxygen species [55]; the NOX4 isoenzyme is mainly expressed in endothelial cells [24]. Interestingly, EDHF synthase/cytochrome P450 epoxygenase is also a source of superoxide anion [43]. In the mid-1980s several groups reported the release of a potent peptidergic vasoconstrictor substance from endothelial cells [51, 58, 99]. The identity of the gene and peptide sequence of this substance, which was named *endothelin* due to its origin, was ultimately revealed by Masaki's group from Japan and was published in 1988 [8, 142]. Subsequently, other members of this peptide family such as endothelin-2 and endothelin-3 were identified [7]. Through the activation of ET_A receptors, endothelin-1 causes sustained and powerful vasoconstriction and also stimulates cell proliferation [7] and mediates endothelium-dependent contractions via *thromboxane A₂* [122]. Most recently, it was shown that endothelial cell-derived ET-1 is responsible for the majority of the endothelin tissue expression, as endothelial cell-specific preproendothelin-1-deficient mice exhibit a reduction of ET-1 tissue levels in several organs up to 70% compared with wild-type mice [70]. The hypotension observed in these animals also indicates that the vasoconstrictor activity outweighs the dilator activities of endothelin. Like endothelin, angiotensin II is also produced by endothelial cells and through the activation of AT₁ receptors has similar vasoconstrictor and growth-promoting effects if its production increases abnormally [41].

Oxidative stress and inflammation: brothers in arms

Generally, either increasing cellular antioxidant capacity or reducing oxidative stress will have similar beneficial effects on the vasculature (Fig. 1). Due to the fact that NO is




Fig. 1 Comparable and potentiating effects of the risk factors obesity and aging on antioxidant capacity (*left*) and oxidative stress (*right*). Both, obesity and aging, lead to a reduction in formation of bioactive NO and prostacyclin. This is further aggravated by increased levels of glucose, endothelin-1, peroxynitrite (formed from the diffusion-limited reaction between superoxide anion and NO), and angiotensin II. As indicated in the figure, this imbalance favors inflammation as a “common denominator” and thus the development of cardiovascular, renal, and metabolic diseases

formed by the multi-enzyme complex NO synthase [45], which concomitantly produces reactive oxygen species through its NADPH oxidase domain, increasing NO bioactivity has been complicated by NO synthase uncoupling [73]. Since the reaction between NO and superoxide anion is essentially diffusion limited, substantial amounts of peroxynitrite (ONOO[−]) are formed [5] (Fig. 1). ONOO[−] causes cell injury through nitrosylation of proteins, which partially or completely inactivates them [1]. Nitrosylation of proteins, which will cause relatively stable nitrotyrosine to be formed, will change the function, structure, and thus, the accessibility of these proteins to interact with other proteins [94]. Beneficial effects of interventions to reduce oxidative stress and inflammation have been shown, among others, for diseases such as atherosclerosis, myocardial infarction, stroke, peripheral vascular disease, arterial hypertension, chronic renal failure, pulmonary arterial hypertension [134], and for a number of disease conditions mainly associated with chronic inflammation such as connective tissue diseases and metabolic conditions such as insulin resistance and diabetes (Fig. 1).

Current and future world demographics of aging and obesity

Over the past centuries, scientists have developed hundreds of theories to explain the aging phenomenon, many of which are based on the notion that age-dependent changes accumulate with time [4]. Due to last century's economic and scientific advances, aging is not the most frequent

cause of death after age 28 [5] as we have managed to live much longer than our ancestors with an average age of currently around 80 years [5]. The physiological aging process is associated with changes in cellular function, metabolic rearrangements, and structural changes in many organs such as the vasculature, the kidney, the brain, and the heart just to name a few. Ten years from now, the majority of deaths worldwide will have a cardiovascular cause, and within the next 40 years, substantial increases in the aged populations are to be expected [5]. Moreover, by 2050 the world's population are expected to increase by 50% to approximately nine billion [5]. This increase, which will be predominately due to the increased longevity [5], will result in aging of the overall world population [5, 52], and include more than one billion postmenopausal women [12] with a high percentage of obese individuals [5, 12]. It will, therefore, be important to control diseases that occur at an increased incidence with aging. Aging not only promotes the development of atherosclerotic vascular disease, but is also associated with significant metabolic changes, resulting in age-dependent increases of body weight, changes of insulin sensitivity, as well as changes in lipid metabolism [4, 5]. Moreover, the prevalence and incidence of hypertension increases in the elderly [12], which is in part due to arterial stiffening [72, 85, 86] and the arterial calcification associated with it [61]. In this regard, arginase—possibly through interactions with BH₄—has been recently proposed as a new therapeutic target to counteract arterial stiffening associated with aging [69, 113]. Since the above changes directly contribute to atherosclerotic burden, it would be possible to explain the increase in vascular disease seen with aging at least in part by these disturbances. That aging is indeed an independent risk factor for coronary artery disease and stroke is perhaps best evident from patients suffering from Werner syndrome or Hutchinson–Gilford progeria. These patients experience much accelerated aging [84, 89, 135] and usually die within 20 years due to myocardial infarction or stroke [68, 108]. A causal link between defective lamin genes and accelerated vascular aging in these conditions has been recently demonstrated [91, 103].

Aging-associated vascular changes: role of endothelial factors

Aging affects many pathways involved in cardiovascular homeostasis and particularly the function of endothelial cells. In fact, endothelial aging is associated with abnormalities in endothelial cell size and shape [57], susceptibility to apoptosis [62], angiogenesis [106], changes in ploidy and telomere length [2], and abnormal release of vasoactive factors [42, 78]. Overall, the balanced released of factors is tipped towards inflammatory activation and cell growth

(Fig. 1). In addition, a number of physiological cardiovascular functions change with increasing age [23, 45].

Mechanisms of endothelial cell dysfunction in aging


Nitric oxide

With age, a number of changes occur in the cardiovascular system that can be considered pro-atherogenic. For instance, the bioactivity of NO decreases and has been considered to be one of the factors contributing to the higher incidence of arterial hypertension, atherosclerosis, and renal disease in aged individuals [4, 83]. Age-related reductions in endothelium-dependent dilation and in NO bioactivity have been shown by Zeiher and coworkers as well as Taddei et al. [123, 144]. We have previously measured, using porphyrinic microsensors, the release of NO from the aortic endothelium of aged rats. We observed that with advanced age in rats—that do not develop atherosclerosis—the stimulated release of NO was reduced by almost 70% [131] (Fig. 2a). This was associated with an attenuation of endothelial dependent relaxation in the same arterial vessel [13, 131]. In contrast to the aorta of rats, endothelium-dependent relaxation to acetylcholine remains unaffected by aging in the femoral artery [13]. We not only studied stimulated NO release [13, 131], but we also found that basal NO release was reduced [13]. Interestingly, the expression of endothelial NO synthase (NOS3) increases with age [54], as does the constitutively expressed inflammatory NO synthase (NOS2) [54] (Fig. 2b). Aortic protein expression of NOS2 and NOS3 also increases with age [31]. The sources of increased O₂^{•−} production in aging arteries are not only enzymes such as NADPH oxidase [65], but also uncoupled NO synthase, which lead to increased formation of O₂^{•−} through its NADPH oxidase domain and possibly involves changes in BH₄ availability [143]. An interesting study in the longest living rodent, which has a life expectancy of up to 26 years compared with 3 to 4 years in other rodents, found that the vasculature of this particular animal expresses much higher amounts of antioxidant enzymes such as SOD [36], suggesting that cellular (but not dietary) antioxidant capacity may indeed be a line of defense against aging-associated cumulative oxidative injury [23, 24]. Finally, other mechanisms such as EDHF appear to take over functions normally attributed to NO with aging in certain vascular beds [50]. Interestingly, in Klotho mice, which show an aging phenotype, only the bioactivity of NO but not prostacyclin is reduced [96].

Endothelin

We found that with aging preproendothelin-1 mRNA expression increases in the vasculature (Fig. 2b) and also

Fig. 2 a Effects of aging on vascular NO bioactivity as measured by amperometry in aortic endothelium of rats aged 6 and 33 months of age. Aging was associated with a dramatic decrease in endothelial NO bioactivity. **b** Effects of aging on the vascular expression of preproendothelin-1 gene and genes of NOS3 (endothelial cell NOS) and NOS2 (inflammatory NOS). In the endothelium-intact vascular preparations of rat aorta an up-regulation of all three genes investigated was observed, $*p < 0.05$ vs. *young*. **c** Anatomic heterogeneity of endothelin-1 peptide expression between the aorta, renal artery, and the carotid artery in young rats (3 months of age, “young”). At 24 months of age, “old” endothelin-peptide levels as measured by RIA and HPLC increased in all three vascular beds investigated, $\dagger p < 0.05$ vs. *aorta*, $p < 0.05$ vs. *renal artery*, $*p < 0.05$ vs. *young*. Figure in part reproduced from Tschudi et al. [131] (Panel a) and Goettsch et al. [54] (Panels b and c), with permission from the American Society of Clinical Investigation and the publishers



in the kidney [54, 75]. Interestingly, endothelin-1 peptide expression markedly differed between the aorta, renal, and carotid artery, in all of which an increase of endothelin-1 peptide expression was found with aging (Fig. 2c) [54, 75]. To determine whether endogenous endothelin plays a role for cellular aging and functional injury (proteinuria) in the kidney *in vivo*, we investigated the

effects of the blockade of endothelin ET_A receptors in the model of established focal segmental glomerulosclerosis [101]. Although it was previously thought that glomerulosclerosis due to aging is an irreversible process, we unexpectedly found that endothelin inhibition not only reversed proteinuria but that it actually induced partial healing of the previously sclerotic glomerulus [101].

These changes were completely independent of blood pressure and renal hemodynamics and indicated that, indeed, endothelin plays a causal role for the structural and functional changes in the aging cardiovascular system, most likely through its trophic effects [6]. Recent evidence further supports a role for endothelin participating in aging-associated vascular functional injury [39] and enhanced vasoconstriction seen with aging [17, 53].

Obesity as a cause of abnormal production and function of endothelial factors

Within a decade, obesity has become one of the most relevant health issues in many countries around the world [9, 88], with the associated health costs exploding [32]. In 2005, 1.6 billion adults worldwide were overweight and 400 million were obese. By 2015, the numbers are expected to increase even further to 2.3 billion adults being overweight and 700 million obese [79, 98, 115, 119, 120]. In both cases, these numbers do not include children and adolescents, in which obesity also has become a worldwide problem [77]. The reasons for this development are economic growth in developing countries as well and as changes in nutritional patterns combined with the availability of inexpensive and unbalanced diets rich in carbohydrates and fat [25, 79, 88, 98, 115, 119, 120]. Frequently, this is combined with unfavorable lifestyles that particularly include lack of physical exercise and consumption of high-caloric beverages and soft drinks [9, 79, 98, 115, 119, 120]. It has been even proposed that because of the continuing increase of obesity that life expectancy might decline by the middle of this century [100, 119]. One of the most worrisome developments is that obesity now increasingly affects school children [67] who, at a young age, present with diseases normally found only in adults of higher age namely, arterial hypertension and diabetes mellitus [9]. In fact, overweight children already prematurely develop abnormal endothelial cell dysfunction and arterial intima-media thickening [141] normally found in obese adults [118]. This already illustrates that obesity may actually mimic aging in certain aspects. The mechanisms involved in the pathophysiology of obesity are numerous [138]. Mechanisms include, abnormal changes in insulin sensitivity, dyslipidemia, increased vasomotor tone, structural abnormalities in the liver (non-alcoholic steatohepatitis), increased sympathetic drive, structural changes in the kidney, and perhaps most importantly, inflammation [138]. Excessive visceral fat is one of the major contributors of these abnormalities, and studies in rodents and in monkeys indicate that either removal of visceral fat or caloric restriction can extend the lifespan in mammals [34, 95].

Mechanisms of endothelial cell dysfunction in obesity

Nitric oxide

Several studies in experimental animals and humans have shown that in obesity the bioactivity of NO is reduced [18, 22, 37, 104]. The mechanistic concept that has been mostly propagated is the inactivation of NO by superoxide anion (O_2^-), leading to the formation of peroxynitrite (Fig. 1). The source of increased O_2^- production is not only enzymes such as NADPH oxidase, but also uncoupled NO synthase [44, 82]. Increased nitrotyrosine formation as a consequence of peroxynitrite production has been described in obese animal models [22, 26, 48]. More recently, other pathways such as guanylate cyclase, the intracellular target of NO (Table 1), have also been shown to be affected by obesity and have been directly linked to inflammation [107].

Endothelin

Experimental studies suggest that animal models exhibit many of the changes seen with obesity in humans, including inflammation, dyslipidemia, and abnormal vasomotor tone [33, 121, 130].

One of the most important factors responsible for the high prevalence of obesity is an increased intake of high-calorie food rich in carbohydrates and fat [37]. There are a number of excellent experimental models of diet-induced obesity in which changes in the vasculature and kidney have been studied [33, 121, 130]. One of our first efforts in the field was to study the effects of high-calorie, high-fat-diet-induced obesity on the renin–angiotensin system and the mouse kidney [14]. We found that obesity increases activity of the angiotensin converting enzyme (ACE) in the kidney and that this regulation is dependent on endothelin ET_A receptors (Fig. 3). These data suggested that—under certain conditions such as obesity—endothelin receptor antagonists also have ACE-inhibitor functions. We also demonstrated that vascular contractility to endothelin increases both in models of diet-induced obesity and in monogenetic leptin deficient obesity with differences between vascular beds [20, 92, 93, 127, 128]. In addition to being a vasoconstrictor, endothelin-1 is a potent pro-atherogenic peptide [11, 16]. As seen in aging arteries—vascular expression of endothelin at the mRNA level and that of ET_A receptors increases in diet-induced obesity [93, 128] (Fig. 4c, d). Experimental studies provide evidence that diet-induced obesity exerts specific changes promoting enhanced vasoconstriction and arterial hypertension as can be seen in obese humans with regard to an activated endothelin pathway [29]. Clinical studies support this notion and suggest possible




Fig. 3 Effects of obesity on the interactions between tissue RAS and the ET system. Obesity activates components of the RAS in adipose tissue, thereby increasing formation of Ang II. Obesity also increases expression/activity of prepro-ET-1 (ppET-1). Endothelin-converting enzyme (ECE) and endothelin-1 is stimulated by Ang II in vivo, thereby increasing production of ET-1. As shown (shaded boxes), ET-1

also stimulates tissue ACE activity, via activation of ET_A receptors. Expression of ppET-1 mRNA is further regulated by ET-1 in an autocrine manner and by NO. Aogen indicates angiotensinogen, (–) inhibition, (+) stimulation. Figure reproduced from Barton et al. [8] with permission from the American Heart Association and the publisher


therapeutic potential for endothelin receptor antagonists in patients with obesity and related complications such as arterial hypertension [16]. In fact, two clinical studies in obese patients (suffering either from arterial hypertension

or diabetic nephropathy) have been most recently published, both showing the beneficial effects of endothelin receptor blockade on renal function and blood pressure [80, 139].

Fig. 4 a Promoting effect of diet-induced obesity (o) on angiotensin II-induced contractions in the aorta (left panel), but not the carotid artery (right panel) in mice. Obesity-induced increases in contractility were completely prevented by in vivo treatment with an orally active endothelin antagonist (darusentan, LU135252, LU) despite continued obesity (O+LU). * $p < 0.05$ vs. lean control (C), † $p < 0.05$ vs. obese (o).

b Diet-induced obesity in mice (filled circles) enhances endothelium-dependent contractions in carotid artery (left panel) and aorta (right panel). * $p < 0.05$ vs. C57 control

c Up-regulation of diet-induced obesity of the preproendothelin gene in mice following diet-induced obesity. **d** Effect of increasing dietary fat content on vascular expression of the angiotensin AT_1 receptor and the endothelin ET_A receptor in a mouse model of diet-induced obesity. Figure panels in part reproduced from Barton et al. [8] (Panel a), Traupe et al. [129] (Panels b and c), and Mundy et al. [93] (Panel d). Reproduced with permission from the American Heart Association and the publishers



Angiotensin

Similar to what can be seen during aging [17] obesity does not equally affect all vascular beds to the same degree. Using the C57 mouse model of diet-induced obesity [121], we found that contractions to angiotensin II markedly increased only in the aorta, but not in the carotid artery [14] (Fig. 4a). Most surprisingly, we found that the increased contractility was completely prevented if animals were concomitantly treated with an endothelin ET_A receptor antagonist [14]. These effects were independent of body weight and arterial blood-pressure, suggesting that endogenous endothelin is activated during obesity and that it contributes to angiotensin-mediated vasoconstriction in selected vascular beds. Contractions to angiotensin and this model were also blocked by cyclooxygenase inhibition *in vitro* to a large degree, suggesting that in the mouse vasculature endothelial EDCFs formed from vasoconstrictor prostanoids contribute to the contractility of other vasoconstrictors [14], an effect that may be age-dependent [71]. Interestingly, the amount of dietary fat content affects aortic protein expression of the AT₁ receptor, which was found to be up-regulated only if the diet contained very high amounts of fat [93] (Fig. 4d).

Vasoconstrictor prostanoids

Enhanced vasoconstriction has been observed in patients with obesity [117] and both cyclooxygenase and endothelin has been implicated in these responses. In obese mice endothelial vasoconstrictor prostanoids are increasingly formed in both aorta and carotid artery (Fig. 4b) [128]. Contractions are sensitive to blockade with nonselective COX inhibition, but not COX-2 selective inhibitors [128]. In a simple and elegant study it was subsequently shown by Vanhoutte's group using COX-1 and COX-2 deficient mice that COX-1 is indeed the enzyme responsible for prostanoid-mediated EDCF production in mice [124]. Our results suggest that with obesity, COX-1 dependent vasoconstrictor pathways become activated and that they contribute to enhanced vasoconstriction as can be seen in obese humans [104]. Again, a similar activation of COX-dependent pathways has been reported to occur with aging [125], which is yet another similarity between the two conditions. Indeed, our recent work comparing functional vascular injury due to obesity in youth and adulthood suggests that obesity indeed causes changes compatible with accelerated, "premature" functional vascular aging [19]. Aside from COX-derived EDCFs, another endothelium-derived arachidonic acid product, prostacyclin, has recently been directly implicated in obesity, by determining the fate for the development of fat cells from progenitor cells [64, 136].

Hydroxyl radical

The role of hydroxyl radical in vascular biology has not been investigated much. We have analyzed the production of hydroxyl radical in normal mice and in monogenetic obesity [92]. We found that endothelin-1 stimulates hydroxyl radical formation and that obesity, more or less, abolishes the stimulating effect of endothelin on hydroxyl radical formation [92]. On the other hand, the relaxant response to hydroxyl radical was enhanced in animals with monogenetic obesity [92]. Similar observations were made in models of diet-induced obesity, where vascular responses to hydroxyl radical changed from contractions in lean animals into relaxations upon treatment with high-fat diet, again effects being specific to a certain vascular beds [20].

"Endothelial therapy" for and aging obesity

Atherosclerosis is a systemic, age-dependent inflammatory vascular process that still accounts for half of the morbidity and mortality in industrialized countries [15]. Atherosclerosis is associated with age-dependent coronary vascular calcification, which shows a gender difference affecting women much less than men [61, 114]. In atherogenesis, inflammation—most likely due to and further augmenting oxidative stress—is one of the main pathophysiological mechanisms propagating disease progression [10] and has been directly implicated in vascular calcification [116]. Early lesions of the atherosclerotic plaque (fatty streaks) consisting of endothelial deposits of lipid-laden macrophages, can be detected in the fetal aorta, and their progression is aggravated by maternal hypercholesterolemia [97] and age. This suggests that lipids are required for disease onset and progression of atherosclerosis already early in life. Importantly, already in children, obesity promotes the development of fatty streaks and coronary atheromata, pathological changes from which surprisingly, girls appear to be protected due to endogenous estrogen production [87].

Despite the lack of scientific evidence, the pharmaceutical and cosmetics industry continues to devote much activity to the economically rewarding field of aging "prevention" (rejuvenation), often also called "anti-aging". There are now even scientific journals dedicating their efforts exclusively towards "rejuvenation" [35]. Despite a general desire for "rejuvenations" that is largely fueled by psychological and social factors, efforts should not be focused on finding potions and remedies [4, 5]. Instead of trying to "turn back time", aging can and should be accepted as a physiological process that does not require intervention but allows a life very worthwhile if the right steps are taken in due time [4, 5]. Not surprisingly, in

elderly humans endothelium-dependent vasoreactivity can be preserved by exercise even at an older age [66]. However, aged individuals frequently exhibit conditions favoring the development of hypertension, dyslipidemia, and atherosclerosis, including a high prevalence of obesity, lack of exercise, and unfavorable dietary regimens [9]. Unfortunately, these conditions are no longer limited to aged individuals, but already present to a considerable degree in children [9, 77]. It will thus require timely and powerful interventions if we want to avoid future disease in adulthood and even later in life. In fact, childhood obesity—even if normal body weight is maintained in later life—increases the likelihood of adult coronary artery disease [3, 21, 77].

A decade ago we proposed the concept of “endothelial therapy” as a means to preserve and/or improve function and reduce production of deleterious endothelium-derived mediators to interfere with atherosclerosis progression [8]. A number of modalities are available to interfere with age-related changes in endothelial cell function [66]. Preventive measures, which apply to children and adolescents as well, include cessation of smoking, normalization of increased body weight, and avoiding unbalanced diets rich in fat and sugars and low in fibers [30]. Interestingly, nutritional additives such as vitamins appear to be largely ineffective to interfere with age-dependent functional changes [4, 5]. As aging is frequently associated with a reduction of physical activity and fitness, it is even more important to emphasize the “therapeutic” role of regular physical activity, which also helps reduce the incidence and improve the severity of related co-morbidities such as diabetes, high blood pressure, dyslipidemia, and obesity [4, 5]. In fact, it has been demonstrated that lack of exercise accelerates most diseases known to show an increased prevalence with aging [76]. Most recent work from Lauf's group suggests that exercise can actually slow down vascular aging [140]. It can be anticipated that maintaining or even improving cardiovascular health with age is not only likely to result in improved general health, but can also be expected to have a positive impact on cardiovascular and renal morbidity and mortality [15, 129], and that it would result in enormous economic benefits for health systems worldwide. Indeed, regular intense exercise has beneficial effects on cardiovascular health showing a dramatic risk reduction [81] that appears to be equally effective in obese individuals. Similarly, weight loss has been shown to improve the vascular risk profile by reducing aortic pulse wave velocity [105].

Changes aiming to achieve normal body weight and improved fitness of the world population will require timely implementation and it also will provide us with a chance to further study endothelial cell biology in the clinical setting more closely in the context of obesity and aging. However,

we must not wait too long to make these changes work. Should we fail to reach the required goals it is well possible that we might—for the first time—experience a decline in the longevity that we have achieved over hundreds of years [100, 119].

Acknowledgment This work was supported by the Swiss National Science Foundation (grants Nr. 3200-108258 and K33KO-122504).

References

1. Abello N, Kerstjens HA, Postma DS, Bischoff R (2009) Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. *J Proteome Res* 8:3222–3238
2. Aviv H, Khan MY, Skurnick J, Okuda K, Kimura M, Gardner J, Priolo L, Aviv A (2001) Age dependent aneuploidy and telomere length of the human vascular endothelium. *Atherosclerosis* 159:281–287
3. Baker JL, Olsen LW, Sorensen TI (2007) Childhood body-mass index and the risk of coronary heart disease in adulthood. *N Engl J Med* 357:2329–2337
4. Barton M (2005) Ageing as a determinant of renal and vascular disease: role of endothelial factors. *Nephrol Dial Transplant* 20:485–490
5. Barton M (2005) Aging and biomedicine 2005: where should we go from here? *Cardiovasc Res* 66:187–189
6. Barton M (2008) Reversal of proteinuric renal disease and the emerging role of endothelin. *Nat Clin Pract Nephrol* 4:490–501
7. Barton M, Furrer J (2003) Cardiovascular consequences of the obesity pandemic: need for action. *Expert Opin Investig Drugs* 12:1757–1759
8. Barton M, Haudenschild C (2001) Endothelium and atherogenesis: endothelial therapy revisited. *J Cardiovasc Pharmacol* 38 (Suppl 2):S23–S25
9. Barton M (2005). Management and prevention of obesity-associated hypertension. *Ren Angiotens Syst Cardiovasc Med* 1:11–14
10. Barton M, Meyer MR (2009) Postmenopausal hypertension: mechanisms and therapy. *Hypertension* 54:11–18
11. Barton M, Yanagisawa M (2008) Endothelin: 20 years from discovery to therapy. *Can J Physiol Pharmacol* 86:485–498
12. Luscher T, Barton M (2000) Endothelin and endothelin antagonists: Therapeutic considerations for a new class of cardiovascular drugs. *Circulation* 102:2434–2440
13. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF (1997) Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. *Hypertension* 30:817–824
14. Barton M, Carmona R, Morawietz H, d'Uscio LV, Goettsch W, Hillen H, Haudenschild CC, Krieger JE, Munter K, Lattmann T, Luscher TF, Shaw S (2000) Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. *Hypertension* 35:329–336
15. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T (2003) Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. *Int J Biochem Cell Biol* 35:826–837
16. Barton M, Traupe T, Haudenschild CC (2003) Endothelin, hypercholesterolemia and atherosclerosis. *Coron Artery Dis* 14:477–490

17. Barton M, Minotti R, Haas E (2007) Inflammation and atherosclerosis. *Circ Res* 101:750–751
18. Bender SB, Herrick EK, Lott ND, Klabunde RE (2007) Diet-induced obesity and diabetes reduce coronary responses to nitric oxide due to reduced bioavailability in isolated mouse hearts. *Diab Obes Metab* 9:688–696
19. Bhattacharya I, Damjanovic M, Gut A, Hager S, Perez-Dominguez A, Minotti R, Haas E, Barton M (2008) Childhood obesity induced by a high-fat diet causes premature vascular aging involving endothelium-dependent mechanisms. *Hypertension* 52:e89
20. Bhattacharya I, Mundy AL, Widmer CC, Kretz M, Barton M (2008) Regional heterogeneity of functional changes in conduit arteries after high-fat diet. *Obesity* (Silver Spring) 16:743–748
21. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L (2007) Adolescent overweight and future adult coronary heart disease. *N Engl J Med* 357:2371–2379
22. Bourgoin F, Bachelard H, Badeau M, Melancon S, Pitre M, Lariviere R, Nadeau A (2008) Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet. *Am J Physiol Heart Circ Physiol* 295:H1044–H1055
23. Brandes RP, Fleming I, Busse R (2005) Endothelial aging. *Cardiovasc Res* 66:286–294
24. Brandes RP, Weissmann N, Schroder K (2010) NADPH oxidases in cardiovascular disease. *Free Radic Biol Med* (in press)
25. Bray GA, Popkin BM (1998) Dietary fat intake does affect obesity! *Am J Clin Nutr* 68:1157–1173
26. Brodsky SV, Gealekman O, Chen J, Zhang F, Togashi N, Crabtree M, Gross SS, Nasjletti A, Goligorsky MS (2004) Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. *Circ Res* 94:377–384
27. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH (2002) EDHF: bringing the concepts together. *Trends Pharmacol Sci* 23:374–380
28. Campbell WB, Fleming I (2010) Epoxyeicosatrienoic acids and endothelium-dependent responses. *Pflugers Arch* 459:881–895
29. Cardillo C, Campia U, Iantorno M, Panza JA (2004) Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. *Hypertension* 43:36–40
30. Chen L, Caballero B, Mitchell DC, Loria C, Lin PH, Champagne CM, Elmer PJ, Ard JD, Batch BC, Anderson CA, Appel LJ (2010) Reducing consumption of sugar-sweetened beverages is associated with reduced blood pressure: a prospective study among United States adults. *Circulation* 121:2398–2406
31. Chou TC, Yen MH, Li CY, Ding YA (1998) Alterations of nitric oxide synthase expression with aging and hypertension in rats. *Hypertension* 31:643–648
32. Colditz GA (1999) Economic costs of obesity and inactivity. *Med Sci Sports Exerc* 31:S663–S667
33. Collins S, Martin TL, Surwit RS, Robidoux J (2004) Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. *Physiol Behav* 81:243–248
34. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. *Science* 325:201–204
35. Cox LS (2009) Live fast, die young: new lessons in mammalian longevity. *Rejuvenation Res* 12:283–288
36. Csiszar A, Labinskyy N, Orosz Z, Xiangmin Z, Buffenstein R, Ungvari Z (2007) Vascular aging in the longest-living rodent, the naked mole rat. *Am J Physiol Heart Circ Physiol* 293:H919–H927
37. Damjanovic M, Barton M (2008) Fat intake and cardiovascular response. *Curr Hypertens Rep* 10:25–31
38. De Mey JG, Vanhoutte PM (1982) Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. *Circ Res* 51:439–447
39. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR (2009) Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. *Am J Physiol Heart Circ Physiol* 297:H425–H432
40. Dusting GJ, Moncada S, Vane JR (1977) Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. *Prostaglandins* 13:3–15
41. Dzau VJ (1993) Vascular renin-angiotensin system and vascular protection. *J Cardiovasc Pharmacol* 22(Suppl 5):S1–S9
42. Erusalimsky JD, Kurz DJ (2006) Endothelial cell senescence. *Handb Exp Pharmacol* 176:213–248
43. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R (2001) Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. *Circ Res* 88:44–51
44. Forstermann U, Munzel T (2006) Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation* 113:1708–1714
45. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H (1994) Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. *Hypertension* 23:1121–1131
46. Furchgott RF (1993) Introduction to EDRF research. *J Cardiovasc Pharmacol* 22:S1–S2
47. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 288:373–376
48. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, Chade AR, Lerman LO, Lerman A (2007) Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. *Am J Physiol Heart Circ Physiol* 292:H904–H911
49. Garg UC, Hassid A (1989) Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. *J Clin Invest* 83:1774–1777
50. Gaubert ML, Sigaud-Roussel D, Tartas M, Berrut G, Saumet JL, Fromy B (2007) Endothelium-derived hyperpolarizing factor as an in vivo back-up mechanism in the cutaneous microcirculation in old mice. *J Physiol* 585:617–626
51. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF (1986) Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. *J Pharmacol Exp Ther* 236:339–343
52. Global population at a glance: 2002 and beyond. The US Census Bureau, US Department of Commerce Economic and Statistics Administration <http://www.census.gov/>. Accessed 13 March 2010
53. Goel A, Su B, Flavahan S, Lowenstein CJ, Berkowitz DE, Flavahan NA (2010) Increased endothelial exocytosis and generation of endothelin-1 contributes to constriction of aged arteries. *Circ Res* (in press)
54. Goettsch W, Lattmann T, Amann K, Szibor M, Morawietz H, Munter K, Muller SP, Shaw S, Barton M (2001) Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: implications for atherosclerosis. *Biochem Biophys Res Commun* 280:908–913
55. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res* 86:494–501

56. Gryglewski RJ, Palmer RM, Moncada S (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. *Nature* 320:454–456
57. Haudenschild CC, Prescott MF, Chobanian AV (1981) Aortic endothelial and subendothelial cells in experimental hypertension and aging. *Hypertension* 3:1148–1153
58. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF (1985) Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. *Am J Physiol* 248:C550–C556
59. Hill-Kapturczak N, Kapturczak MH, Block ER, Patel JM, Malinski T, Madsen KM, Tisher CC (1999) Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. *J Am Soc Nephrol* 10:481–491
60. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F (1993) Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J Clin Invest* 91:1367–1373
61. Hoff JA, Chomka EV, Krainik AJ, Daviglus M, Rich S, Kondos GT (2001) Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. *Am J Cardiol* 87:1335–1339
62. Hoffmann J, Haendeler J, Aicher A, Rossig L, Vasa M, Zeiher AM, Dimmeler S (2001) Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. *Circ Res* 89:709–715
63. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci USA* 84:9265–9269
64. Ishibashi J, Seale P (2010) Medicine. Beige can be slimming. *Science* 328:1113–1114
65. Jacobson A, Yan C, Gao Q, Rincon-Skinner T, Rivera A, Edwards J, Huang A, Kaley G, Sun D (2007) Aging enhances pressure-induced arterial superoxide formation. *Am J Physiol Heart Circ Physiol* 293:H1344–H1350
66. Jensen-Urstad K, Bouvier F, Jensen-Urstad M (1999) Preserved vascular reactivity in elderly male athletes. *Scand J Med Sci Sports* 9:88–91
67. Jolliffe D (2004) Extent of overweight among US children and adolescents from 1971 to 2000. *Int J Obes Relat Metab Disord* 28:4–9
68. Keay AJ, Oliver MF, Boyd GS (1955) Progeria and atherosclerosis. *Arch Dis Child* 30:410–414
69. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, Santhanam L, Webb A, Camara A, Sikka G, Nyhan D, Shoukas AA, Ilies M, Christianson DW, Champion HC, Berkowitz DE (2009) Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. *J Appl Physiol* 107:1249–1257
70. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, Kedzierski RM, Hammer RE, Yanagisawa H, Williams SC, Richardson JA, Suzuki T, Yanagisawa M (2010) Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. *Hypertension* 56(1):121–128
71. Kretz M, Mundy AL, Widmer CC, Barton M (2006) Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice. *J Cardiovasc Pharmacol* 48:30–33
72. Lakatta EG (1989) Arterial pressure and aging. *Int J Cardiol* 25 (Suppl 1):S81–S89
73. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 111:1201–1209
74. Larsen BT, Guterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, Manthathi VL, Falck JR, Miura H (2008) Hydrogen peroxide inhibits cytochrome p450 epoxigenases: interaction between two endothelium-derived hyperpolarizing factors. *Circ Res* 102:59–67
75. Lattmann T, Shaw S, Munter K, Vetter W, Barton M (2005) Anatomically distinct activation of endothelin-3 and the l-arginine/nitric oxide pathway in the kidney with advanced aging. *Biochem Biophys Res Commun* 327:234–241
76. Laufs U, Wassmann S, Czech T, Munzel T, Eisenhauer M, Bohm M, Nickenig G (2005) Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. *Arterioscler Thromb Vasc Biol* 25:809–814
77. Ludwig DS (2007) Childhood obesity—the shape of things to come. *N Engl J Med* 357:2325–2327
78. Luscher TF, Barton M (1997) Biology of the endothelium. *Clin Cardiol* 20:II-3–10
79. Malik VS, Popkin BM, Bray GA, Despres JP, Hu FB (2010) Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. *Circulation* 121:1356–1364
80. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G (2010) Avasentan for overt diabetic nephropathy. *J Am Soc Nephrol* 21:527–535
81. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS (2002) Walking compared with vigorous exercise for the prevention of cardiovascular events in women. *New Engl J Med* 347:716–724
82. Martins MA, Catta-Preta M, Mandarim-de-Lacerda CA, Aguila MB, Brunini TC, Mendes-Ribeiro AC (2010) High fat diets modulate nitric oxide biosynthesis and antioxidant defence in red blood cells from C57BL/6 mice. *Arch Biochem Biophys* 499(1–2):56–61
83. McCann SM, Mastronardi C, de Laurentiis A, Rettori V (2005) The nitric oxide theory of aging revisited. *Ann NY Acad Sci* 1057:64–84
84. McClintock D, Gordon LB, Djabali K (2006) Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. *Proc Natl Acad Sci USA* 103:2154–2159
85. McEniery CM, Yasmin HIR, Qasem A, Wilkinson IB, Cockcroft JR (2005) Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). *J Am Coll Cardiol* 46:1753–1760
86. McEniery CM, Spratt M, Munnery M, Yarnell J, Lowe GD, Rumley A, Gallacher J, Ben-Shlomo Y, Cockcroft JR, Wilkinson IB (2010) An analysis of prospective risk factors for aortic stiffness in men. 20-year follow-up from the Caerphilly prospective study. *Hypertension* 56(1):36–43
87. McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP (2002) Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation* 105:2712–2718
88. McLellan F (2002) Obesity rising to alarming levels around the world. *Lancet* 359:1412
89. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. *N Engl J Med* 358:592–604
90. Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature* 263:663–665
91. Mounkes LC, Kozlov S, Hernandez L, Sullivan T, Stewart CL (2003) A progeroid syndrome in mice is caused by defects in A-type lamins. *Nature* 423:298–301

92. Mundy AL, Haas E, Bhattacharya I, Widmer CC, Kretz M, Baumann K, Barton M (2007) Endothelin stimulates vascular hydroxyl radical formation: effect of obesity. *Am J Physiol Regul Integr Comp Physiol* 293:R2218–R2224
93. Mundy AL, Haas E, Bhattacharya I, Widmer CC, Kretz M, Hofmann-Lehmann R, Minotti R, Barton M (2007) Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: implications for diet-induced obesity. *Cardiovasc Res* 73:368–375
94. Musci G, Persichini T, Casadei M, Mazzone V, Venturini G, Polticelli F, Colasanti M (2006) Nitrosative/oxidative modifications and ageing. *Mech Ageing Dev* 127:544–551
95. Muzumdar R, Allison DB, Huffman DM, Ma X, Atzmon G, Einstein FH, Fishman S, Poduval AD, McVei T, Keith WW, Barzilai N (2008) Visceral adipose tissue modulates mammalian longevity. *Aging Cell* 7:438–440
96. Nakamura T, Saito Y, Ohyama Y, Masuda H, Sumino H, Kuro-o M, Nabeshima Y, Nagai R, Kurabayashi M (2002) Production of nitric oxide, but not prostacyclin, is reduced in *klotho* mice. *Jpn J Pharmacol* 89:149–156
97. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W (1999) Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. *Lancet* 354:1234–1241
98. Nilius B, Serban DN, Vanhoutte PM, Robert F (2010) Furchgott and his heritage: endothelial vasomotor control. *Pflügers Arch* 459:785–786
99. O'Brien RF, Robbins RJ, McMurtry IF (1987) Endothelial cells in culture produce a vasoconstrictor substance. *J Cell Physiol* 132:263–270
100. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS (2005) A potential decline in life expectancy in the United States in the 21st century. *N Engl J Med* 352:1138–1145
101. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M (2004) Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. *Hypertension* 44:974–981
102. Patel JM, Martens JR, Li YD, Gelband CH, Raizada MK, Block ER (1998) Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. *Am J Physiol* 275:L1061–L1068
103. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Shroff R, Skepper J, Shanahan CM (2010) Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. *Circulation* 121:2200–2210
104. Rask-Madsen C, King GL (2007) Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. *Nat Clin Pract Endocrinol Metab* 3:46–56
105. Rider OJ, Tayal U, Francis JM, Ali MK, Robinson MR, Byrne JP, Clarke K, Neubauer S (2010) The effect of obesity and weight loss on aortic pulse wave velocity as assessed by magnetic resonance imaging. *Obesity* (Silver Spring) (in press)
106. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM (1999) Age-dependent impairment of angiogenesis. *Circulation* 99:111–120
107. Rizzo NO, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S, Daum G, Handa P, Schwartz MW, Kim F (2010) Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. *Arterioscler Thromb Vasc Biol* 30:758–765
108. Rosman NP, Anselm I, Bhadelia RA (2001) Progressive intracranial vascular disease with strokes and seizures in a boy with progeria. *J Child Neurol* 16:212–215
109. Ross R (1999) Atherosclerosis—an inflammatory disease. *N Engl J Med* 340:115–126
110. Ross R, Glomset JA (1973) Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. *Science* 180:1332–1339
111. Rubanyi GM, Vanhoutte PM (1986) Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. *Am J Physiol* 250:H822–H827
112. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. *Hypertension* 49:185–192
113. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE (2008) Arginase and vascular aging. *J Appl Physiol* 105:1632–1642
114. Schmermund A, Erbel R, Silber S (2002) Age and gender distribution of coronary artery calcium measured by four-slice computed tomography in 2,030 persons with no symptoms of coronary artery disease. *Am J Cardiol* 90:168–173
115. Serban DN, Nilius B, Vanhoutte PM (2010) The endothelial saga: the past, the present, the future. *Pflügers Arch* 459:787–792
116. Shao JS, Cheng SL, Sadhu J, Towler DA (2010) Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. *Hypertension* 55:579–592
117. Sivitz WI, Wayson SM, Bayless ML, Sinkey CA, Haynes WG (2007) Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction arterial dysfunction in obesity and diabetes. *J Diab Complications* 21:149–157
118. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest* 97:2601–2610
119. Stewart ST, Woodward RM, Rosen AB, Cutler DM (2008) The impact of symptoms and impairments on overall health in US national health data. *Med Care* 46:954–962
120. Stewart ST, Cutler DM, Rosen AB (2009) Forecasting the effects of obesity and smoking on U.S. life expectancy. *N Engl J Med* 361:2252–2260
121. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN (1988) Diet-induced type II diabetes in C57BL/6J mice. *Diabetes* 37:1163–1167
122. Taddei S, Vanhoutte PM (1993) Endothelium-dependent contractions to endothelin in the rat aorta are mediated by thromboxane A₂. *J Cardiovasc Pharmacol* 22:S328–S331
123. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, Salvetti A (2001) Age-related reduction of NO availability and oxidative stress in humans. *Hypertension* 38:274–279
124. Tang EH, Vanhoutte PM (2008) Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. *Physiol Genomics* 32:409–418
125. Tang EH, Ku DD, Tipoe GL, Feletou M, Man RY, Vanhoutte PM (2005) Endothelium-dependent contractions occur in the aorta of wild-type and COX2^{-/-} knockout but not COX1^{-/-} knockout mice. *J Cardiovasc Pharmacol* 46:761–765
126. Toda N (1974) The action of vasodilating drugs on isolated basilar, coronary and mesenteric arteries of the dog. *J Pharmacol Exp Ther* 191:139–146
127. Traupe T, D'Uscio L, Muenster K, Morawietz H, Vetter W, Barton M (2002) Effects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelin. *Cli Sci (Lond)* 1(Suppl 103):13–15
128. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M (2002) Obesity increases prostanoid-

- mediated vasoconstriction and vascular thromboxane receptor gene expression. *J Hypertens* 20:2239–2245
129. Traupe T, Ortmann J, Munter K, Barton M (2003) Endothelial therapy of atherosclerosis and its risk factors. *Curr Vasc Pharmacol* 1:111–121
 130. Tschop M, Heiman ML (2001) Rodent obesity models: an overview. *Exp Clin Endocrinol Diab* 109:307–319
 131. Tschudi MR, Barton M, Bersinger NA, Moreau P, Cosentino F, Noll G, Malinski T, Luscher TF (1996) Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. *J Clin Invest* 98:899–905
 132. Vane JR, Bunting S, Moncada S (1982) Prostacyclin in physiology and pathophysiology. *Int Rev Exp Pathol* 23:161–207
 133. Vanhoutte PM (1974) Inhibition by acetylcholine of adrenergic neurotransmission in vascular smooth muscle. *Circ Res* 34:317–326
 134. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M (2009) Endothelial dysfunction and vascular disease. *Acta Physiol (Oxf)* 196:193–222
 135. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, Wight TN, Nabel EG, Collins FS (2006) Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson–Gilford progeria syndrome. *Proc Natl Acad Sci USA* 103:3250–3255
 136. Vegiopoulos A, Muller-Decker K, Strzoda D, Schmitt I, Chichelnitskiy E, Ostertag A, Berriel Diaz M, Rozman J, Hrabe de Angelis M, Nusing RM, Meyer CW, Wahli W, Klingenspor M, Herzig S (2010) Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. *Science* 328:1158–1161
 137. Vinh A, Widdop RE, Drummond GR, Gaspari TA (2008) Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. *Cardiovasc Res* 77:178–187
 138. Visscher TL, Seidell JC (2001) The public health impact of obesity. *Annu Rev Public Health* 22:355–375
 139. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. *Lancet* 374:1423–1431
 140. Werner C, Furster T, Widmann T, Poss J, Roggia C, Hanhoun M, Scharhag J, Buchner N, Meyer T, Kindermann W, Haendeler J, Böhm M, Laufs U (2009) Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. *Circulation* 120:2438–2447
 141. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, Celermajer DS (2004) Overweight in children is associated with arterial endothelial dysfunction and intima-media thickening. *Int J Obes Relat Metab Disord* 28: 852–857
 142. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332:411–415
 143. Yang YM, Huang A, Kaley G, Sun D (2009) eNOS uncoupling and endothelial dysfunction in aged vessels. *Am J Physiol Heart Circ Physiol* 297:H1829–H1836
 144. Zeiher AM, Drexler H, Saurbier B, Just H (1993) Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. *J Clin Invest* 92:652–662